Reading view
What do early data from Utah’s Doctronic AI pilot show?
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
Good morning health tech readers!


© Adobe
PALoRA: Projection-Adaptive LoRA for Preserving Reasoning in Large Language Models
When Can We Trust Early Warnings? Leakage-Excluded Early Outcome Prediction from LMS Interaction Logs
Teaching Through Analogies: A Modular Pipeline for Educational Analogy Generation
TRAFA: Anticipating User Actions to Reduce Errors in Procedural Tasks with Predictive Feedback
TS-Skill: A Benchmark for Evaluating Analytical Skills in Time-Series Question Answering
Everything at Every Scale: Scale-Invariant Diffusion with Continuous Super-Resolution
Teaching large language models to reason like expert diagnosticians
JEPA-DNA: Grounding Genomic Foundation Models through Joint-Embedding Predictive Architectures
Poland’s economy is thriving, but its science is dying
Nature, Published online: 26 May 2026; doi:10.1038/d41586-026-01664-9
Poland’s economy is thriving, but its science is dyingReprogramming temozolomide response in glioblastoma through regulated and immunogenic cell death modalities
Cell Death Discovery, Published online: 26 May 2026; doi:10.1038/s41420-026-03151-6
Reprogramming temozolomide response in glioblastoma through regulated and immunogenic cell death modalitiesFetal monitoring for high-risk pregnancies using a wearable ultrasound patch
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03140-1
A wearable ultrasound device is optimized for continuous monitoring of pregnancies.What ClickUp’s mass layoff tells us about the future of work
How to breathe life back into brain theory
Nature, Published online: 25 May 2026; doi:10.1038/d41586-026-01619-0
Neuroscience needs to stop treating the brain as if it is a computer.Hippocampal small RNAs from patients with schizophrenia induce specific cognitive and neural phenotypes in mice
Cell Death Discovery, Published online: 25 May 2026; doi:10.1038/s41420-026-03166-z
Hippocampal small RNAs from patients with schizophrenia induce specific cognitive and neural phenotypes in miceGemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial
Nature Cancer, Published online: 25 May 2026; doi:10.1038/s43018-026-01165-8
In this phase 2 trial, Perez et al. reported the safety of the vitamin D receptor agonist paricalcitol with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma and the pharmacodynamic effects of paricalcitol in fibroblasts and immune cells.De novo design of miniproteins targeting GPCRs
Nature, Published online: 21 May 2026; doi:10.1038/s41586-026-10656-8
De novo design of miniproteins targeting GPCRsEbola outbreak: the data that show why researchers are so alarmed
Nature, Published online: 21 May 2026; doi:10.1038/d41586-026-01646-x
The size of the outbreak in its initial days is worrying researchers. The next few weeks will determine how large it grows, they say.Dual ctDNA and CTCs analysis for minimal residual disease detection and relapse monitoring in early-stage breast cancer
NPJ Breast Cancer. 2026 May 20. doi: 10.1038/s41523-026-00970-9. Online ahead of print.
ABSTRACT
Early detection of minimal residual disease (MRD) by liquid biopsy could enable earlier relapse identification in early-stage breast cancer (BC), but most approaches are single-analyte. We prospectively studied 58 patients with early-stage BC, including HR+/HER2-, triple-negative, and HER2+ subtypes, treated with neoadjuvant chemotherapy or primary surgery plus adjuvant therapy. Patient-specific droplet digital PCR assays were designed for both ctDNA and CTCs analysis, with one truncal tumour mutation tracked per patient for detection in both analytes, in serial high-volume blood samples collected at diagnosis before treatment, approximately 1 month after surgery, and at 6-month intervals during follow-up in patients at high risk of relapse. We developed a composite Liquid biopsy Minimal Residual Disease (L-MRD) score integrating six clinical and molecular variables. At baseline (pre-treatment), ctDNA and/or CTCs were detected in 67.2% of patients and remained positive post-surgery in 53.6%. During follow-up, MRD detection anticipated all relapses (100% sensitivity; median lead time 27.95 months) and the L-MRD score stratified 5-year recurrence risk (2.2% vs 41.6%; HR = 6.6; P = 0.04) with strong performance (AUC = 0.891; NPV = 97.8%). This dual-analyte, longitudinal MRD strategy improves relapse prediction and supports further research regarding the clinical utility of personalised surveillance in early-stage BC.
PMID:42161983 | DOI:10.1038/s41523-026-00970-9